GALNT16 and hepatocellular carcinoma: Overall, our study highlights the critical function of the YY1/GALNT16/PD‐L1 axis in HCC immunotherapeutic resistance, particularly the mechanism of GALNT16‐mediated modification of PD‐L1 glycosylation, which offers a potential explanation for the discrepancy between PD‐L1 expression levels and anti‐PD‐1 immunotherapy efficacy.